You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myeloablative Autologous Gene Editing

Showing 26 - 50 of 9,686
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Retinitis Pigmentosa Trial (ZVS203e)

Not yet recruiting
  • Retinitis Pigmentosa
  • (no location specified)
Mar 27, 2023

Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Nashville (CTX001)

Recruiting
  • Beta-Thalassemia
  • +4 more
  • CTX001
  • Nashville, Tennessee
  • +5 more
Feb 2, 2023

Mucopolysaccharidosis II, MPS II Trial in United States (SB-913)

Terminated
Has Results
  • Mucopolysaccharidosis II
  • MPS II
  • SB-913
  • Oakland, California
  • +4 more
Oct 21, 2022

Sickle Cell Disease, Hemoglobinopathies Trial in Canada, United States (EDIT-301)

Recruiting
  • Sickle Cell Disease
  • Hemoglobinopathies
  • EDIT-301
  • Oakland, California
  • +18 more
Jan 10, 2023

Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))

Recruiting
  • Transfusion Dependent Beta-Thalassemia
  • GMCN-508B (LentiRed)
  • Nanning, Guangxi, China
    The affiliated hospital of guangxi medical university
Feb 28, 2023

Cervical Carcinoma Trial in Worldwide (LN-145, LN-145 + pembrolizumab)

Recruiting
  • Cervical Carcinoma
  • LN-145
  • LN-145 + pembrolizumab
  • Phoenix, Arizona
  • +39 more
Aug 16, 2022

Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Tumors Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL))

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Tumor Infiltrating Lymphocytes (TIL)
  • Pittsburgh, Pennsylvania
    Allyson Welsch
Jul 21, 2022

Leukocyte Adhesion Defect - Type I Trial in Los Angeles, Madrid, London (RP-L201)

Active, not recruiting
  • Leukocyte Adhesion Defect - Type I
  • RP-L201
  • Los Angeles, California
  • +2 more
Nov 19, 2021

Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major Trial in Nashville (EDIT-301)

Recruiting
  • Transfusion Dependent Beta Thalassemia
  • +3 more
  • EDIT-301
  • Oakland, California
  • +3 more
Jan 3, 2023

Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)

Active, not recruiting
  • Beta-Thalassemia
  • +4 more
  • CTX001
  • Stanford, California
  • +11 more
Nov 30, 2022

Transfusion Dependent Beta-thalassemia Trial in United States (ST-400 Investigational product)

Active, not recruiting
  • Transfusion Dependent Beta-thalassemia
  • ST-400 Investigational product
  • Los Angeles, California
  • +5 more
Jul 6, 2022

Severe Combined Immunodeficiency Due to ADA Deficiency Trial in London (Infusion of autologous cryopreserved EFS-ADA LV CD34+

Active, not recruiting
  • Severe Combined Immunodeficiency Due to ADA Deficiency
  • Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)
  • +2 more
  • London, United Kingdom
    Great Ormond Street Hospital for Children NHS Foundation Trust
Dec 17, 2021

Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance Trial in Nashville (CTX001)

Recruiting
  • Sickle Cell Disease
  • +4 more
  • CTX001
  • Philadelphia, Pennsylvania
  • +3 more
Jan 24, 2023

Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)

Active, not recruiting
  • Sickle Cell Disease
  • DREPAGLOBE drug product
  • Paris, France
    Department of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022

Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)

Not yet recruiting
  • Beta-Thalassemia
  • +6 more
  • CTX001
  • (no location specified)
Jul 26, 2022

Sickle Cell Disease Trial in Los Angeles, Boston (single infusion of autologous bone marrow derived CD34+ HSC cells transduced

Active, not recruiting
  • Sickle Cell Disease
  • single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
  • Los Angeles, California
  • +1 more
Feb 8, 2022

Neovascular Age-related Macular Degeneration(nAMD) Trial in Shanghai, Tianjin (HG202)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration(nAMD)
  • HG202
  • Shanghai, Shanghai, China
  • +1 more
Sep 4, 2023

Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia Trial in Auckland,

Recruiting
  • Heterozygous Familial Hypercholesterolemia
  • +2 more
  • Auckland, New Zealand
  • +1 more
Aug 4, 2022

Neuroblastoma Trial in Minneapolis (Thiotepa, Cyclophosphamide, Melphalan)

Recruiting
  • Neuroblastoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Transfusion-dependent a-Thalassemia Trial (GMCN-508A Drug Product)

Not yet recruiting
  • Transfusion-dependent α-Thalassemia
  • GMCN-508A Drug Product
  • (no location specified)
Feb 24, 2023

Mucopolysaccharidosis II Trial (Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII)

Not yet recruiting
  • Mucopolysaccharidosis II
  • Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
  • (no location specified)
Dec 16, 2022

Transfusion-dependent Beta-Thalassemia Trial in Tianjin (KL003 cell injection Drug Product)

Not yet recruiting
  • Transfusion-dependent Beta-Thalassemia
  • KL003 cell injection Drug Product
  • Tianjin, Tianjin, China
    Regenerative Medicine Center
May 8, 2023

Hemophilia B Trial in Washington (SB-FIX)

Terminated
  • Hemophilia B
  • SB-FIX
  • Washington, District of Columbia
    Georgetown University Medical Center
Mar 8, 2022

Wiskott-Aldrich Syndrome Trial in Atlanta, Milan (OTL-103)

Active, not recruiting
  • Wiskott-Aldrich Syndrome
  • OTL-103
  • Atlanta, Georgia
  • +1 more
Sep 27, 2022

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023